Silverback Therapeutics, Inc. SBTX
Institutional shares held
76.6 Million
112K
calls
240K
puts
Total value of holdings
$0
$0
calls
$0
puts
Market Cap
N/A
Institutional ownership
215.95%
# of Institutions
196
We take great care to ensure that the data presented and summarized in this overview for Silverback Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SBTX
View all-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY10.5MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
-
Alliancebernstein L.P. New York, NY3.92MShares$00.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.49MShares$00.0% of portfolio
-
State Street Corp Boston, MA2.03MShares$00.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.86MShares$00.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.6MShares$00.0% of portfolio
Latest Institutional Activity in SBTX
Top Purchases
Top Sells
About SBTX
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Transactions at SBTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 07
2025
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
50,002
-19.21%
|
$600,024
$12.3 P/Share
|
|
Apr 07
2025
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
50,002
+9.18%
|
$200,008
$4.85 P/Share
|
|
Mar 20
2025
|
Eric Karas Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-56.51%
|
$140,000
$14.0 P/Share
|
|
Mar 20
2025
|
Eric Karas Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.11%
|
$10,000
$1.5 P/Share
|
|
Mar 06
2025
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
49,600
-19.08%
|
$545,600
$11.21 P/Share
|
|
Mar 06
2025
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
49,600
+16.02%
|
$198,400
$4.85 P/Share
|
|
Mar 05
2025
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
400
-0.19%
|
$4,400
$11.0 P/Share
|
|
Mar 05
2025
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.19%
|
$1,600
$4.85 P/Share
|
|
Feb 03
2025
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
50,000
-19.21%
|
$600,000
$12.31 P/Share
|
|
Feb 03
2025
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.78%
|
$200,000
$4.0 P/Share
|
|
Jan 06
2025
|
Laura Shawver |
SELL
Open market or private sale
|
Direct |
50,000
-19.21%
|
$550,000
$11.1 P/Share
|
|
Jan 06
2025
|
Laura Shawver |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+16.11%
|
$150,000
$3.15 P/Share
|
|
Dec 17
2024
|
Richard E Lowenthal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$1,100,000
$11.67 P/Share
|
|
Dec 17
2024
|
Sarina Tanimoto CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$1,100,000
$11.67 P/Share
|
|
Dec 13
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
27,272
-16.66%
|
$327,264
$12.06 P/Share
|
|
Dec 13
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,272
+14.28%
|
$27,272
$1.44 P/Share
|
|
Dec 12
2024
|
Brian Dorsey Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-80.58%
|
$300,000
$12.3 P/Share
|
|
Dec 12
2024
|
Brian Dorsey Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+44.62%
|
$0
$0.64 P/Share
|
|
Dec 12
2024
|
Justin Chakma Chief Business Officer |
SELL
Open market or private sale
|
Direct |
117,333
-46.25%
|
$1,407,996
$12.27 P/Share
|
|
Dec 12
2024
|
Justin Chakma Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
117,333
+31.62%
|
$0
$0.84 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.42M
Shares
From
8
Insiders
| Exercise of conversion of derivative security | 1.09M shares |
|---|---|
| Bona fide gift | 1.33M shares |
Sell / Disposition
13M
Shares
From
12
Insiders
| Open market or private sale | 6.36M shares |
|---|---|
| Bona fide gift | 4M shares |
| Other acquisition or disposition | 2.67M shares |